Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797730 | 0.88 | ATR (0.44) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30869074 | 0.86 | ATR (0.43) | ATRBRD4TLR2TLR1CNR2 | |
| SCHEMBL30797851 | 0.85 | ATR (0.43) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30797974 | 0.85 | ATR (0.44) | ATRSCN9ABRD4TLR2TLR1 | |
| SCHEMBL30797688 | 0.85 | ATR (0.44) | ATRDDB1CRBNSCN9ABRD4 | |
| SCHEMBL30797897 | 0.85 | ATR (0.46) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30869032 | 0.84 | ATR (0.42) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30869070 | 0.84 | ATR (0.42) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30869139 | 0.84 | ATR (0.42) | ATRDDB1CRBNBRD4TLR2 | |
| SCHEMBL30797547 | 0.84 | ATR (0.42) | ATRSCN9ABRD4TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | ATR 984/4885DDB1 577/4885CRBN 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.